Panacos Pharmaceuticals Net Income
| PANC Stock | USD 0.0001 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Panacos Pharmaceuticals, as well as the relationship between them.
Panacos Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Revenue | Earnings Share (0.01) | Quarterly Revenue Growth (0.20) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -33.7 M | -35.4 M | |
| Net Loss | -33.7 M | -35.4 M | |
| Net Loss | -33.7 M | -35.4 M | |
| Net Loss | (0.63) | (0.67) |
Panacos | Net Income | Build AI portfolio with Panacos Stock |
Analyzing Panacos Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Panacos Pharmaceuticals's current valuation and future prospects.
Latest Panacos Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Panacos Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Panacos Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Panacos Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Panacos Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Panacos Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (37.46 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Panacos Net Income Regression Statistics
| Arithmetic Mean | (35,622,109) | |
| Coefficient Of Variation | (17.29) | |
| Mean Deviation | 3,025,467 | |
| Median | (37,459,000) | |
| Standard Deviation | 6,160,067 | |
| Sample Variance | 37.9T | |
| Range | 25.4M | |
| R-Value | (0.32) | |
| Mean Square Error | 36.3T | |
| R-Squared | 0.10 | |
| Significance | 0.21 | |
| Slope | (393,786) | |
| Total Sum of Squares | 607.1T |
Panacos Net Income History
Other Fundumenentals of Panacos Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Panacos Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Panacos Pharmaceuticals is extremely important. It helps to project a fair market value of Panacos Stock properly, considering its historical fundamentals such as Net Income. Since Panacos Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Panacos Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Panacos Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Panacos diversify its offerings? Factors like these will boost the valuation of Panacos Pharmaceuticals. Anticipated expansion of Panacos directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Panacos Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.01) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Panacos Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Panacos's accounting equity. The concept of intrinsic value - what Panacos Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Panacos Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Panacos Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Panacos Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Panacos Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Panacos Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Panacos Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Panacos Pharmaceuticals.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Panacos Pharmaceuticals on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Panacos Pharmaceuticals or generate 0.0% return on investment in Panacos Pharmaceuticals over 90 days. Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of sm... More
Panacos Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Panacos Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Panacos Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Panacos Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Panacos Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Panacos Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Panacos Pharmaceuticals historical prices to predict the future Panacos Pharmaceuticals' volatility.Panacos Pharmaceuticals Backtested Returns
We have found three technical indicators for Panacos Pharmaceuticals, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Panacos Pharmaceuticals are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Panacos Pharmaceuticals has perfect predictability. Overlapping area represents the amount of predictability between Panacos Pharmaceuticals time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Panacos Pharmaceuticals price movement. The serial correlation of 1.0 indicates that 100.0% of current Panacos Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Panacos Operating Income
Operating Income |
|
Based on the recorded statements, Panacos Pharmaceuticals reported net income of (37.46 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
Panacos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Panacos Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Panacos Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Panacos Pharmaceuticals by comparing valuation metrics of similar companies.Panacos Pharmaceuticals is currently under evaluation in net income category among its peers.
Panacos Fundamentals
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (315.46) % | ||||
| Current Valuation | 321.84 K | ||||
| Number Of Shares Shorted | 107.88 K | ||||
| Price To Earning | (1.33) X | ||||
| Price To Sales | 3.25 X | ||||
| Revenue | 180 K | ||||
| Gross Profit | 99 K | ||||
| EBITDA | (33.84 M) | ||||
| Net Income | (37.46 M) | ||||
| Cash And Equivalents | 26.89 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 358 K | ||||
| Debt To Equity | 3.45 % | ||||
| Current Ratio | 2.15 X | ||||
| Book Value Per Share | 0.1 X | ||||
| Cash Flow From Operations | (31.04 M) | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 41 | ||||
| Beta | -18.76 | ||||
| Market Capitalization | 321.84 K | ||||
| Total Asset | 55.71 M | ||||
| Retained Earnings | (160.02 M) | ||||
| Working Capital | 14.7 M | ||||
| Current Asset | 27.52 M | ||||
| Current Liabilities | 12.82 M | ||||
| Net Asset | 55.71 M |
About Panacos Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Panacos Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Panacos Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Panacos Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Panacos Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Panacos Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Panacos Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Panacos Pharmaceuticals Stock:Check out For information on how to trade Panacos Stock refer to our How to Trade Panacos Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Panacos diversify its offerings? Factors like these will boost the valuation of Panacos Pharmaceuticals. Anticipated expansion of Panacos directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Panacos Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.01) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Panacos Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Panacos's accounting equity. The concept of intrinsic value - what Panacos Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Panacos Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Panacos Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Panacos Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Panacos Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.